Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:O76050 (
neu
)
3,969
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Authors describe the clinico-pathological and immunohistochemical findings of two mediastinal (
seminoma
and yolk-sack) and a pineal mixed (
seminoma
and yolk-sack) tumours. In the mediastinal yolk-sack tumour the light microscopic picture of cellular components, alpha-fetoprotein (AFP), haemoglobin F (Hgb F), blood group antigen, carcinoembryonal antigen (CEA), post-digestion (neuraminidase) peanut antigen (
neu
-PNA) positivities suggest hepatic and intestinal differentiation. In some cells of mediastinal
seminoma
the glucose- and mannose-binding concanavalin-A (Con A) showed reaction. In the mixed tumour of the pineal region in addition to AFP positive cell cords some cell groups reacted with Leu-M1 (CD15) monoclonal antibodies raised against stage specific embryonic antigen 1 (SSEA1).
...
PMID:[Extra-gonadal germ-cell tumors]. 267 89
Testicular germ cell tumors represent the most frequent malignancy in young males aged 20-35 years. Despite the considerably high cure rates provided by platinum-based chemotherapy, 20-30% of cases with advanced disease do not achieve a long-term disease-free survival with first-line chemotherapy. These patients are candidates for conventional-dose or high-dose salvage chemotherapy. The current conventional-dose salvage regimens of reference are the vinblastine-ifosfamide-cisplatin or etoposide-ifosfamide-cisplatin combinations, which are expected to cure approximately 25% of non-seminomatous germ-cell tumour patients. Paclitaxel has also been proved effective both as monotherapy in heavily-pretreated cases and as part of first-line salvage regimens; the combination of paclitaxel-ifosfamide-cisplatin, followed or not by high-dose chemotherapy, induced a favorable long-term disease-free survival rate, especially in patients with good prognosis. Newer cytotoxic drugs, such as gemcitabine and oxaliplatin have also been proved effective, while other agents, such as temozolamide, or targeted therapies, such as trastuzumab in cases over-expressing HER2/
neu
(20% of relapsing germ-cell tumors) are currently under evaluation.
Seminomas
have generally a better prognosis than non-seminomatous tumors and salvage therapy is expected to cure about 50% of all cases.
...
PMID:Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors. 1596 36